Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients

被引：1
|
作者：
Gorgulho, Joao [1 ]
von Felden, Johann [2 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Med Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Med Gastroenterol & Hepatol, Hamburg, Germany
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 60卷 / 10期
关键词：
D O I：
10.1111/apt.18296
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1467 / 1468
页数：2
相关论文
共 50 条
  • [21] The comparative efficacy of atezolizumab and bevacizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC).
    Trueman, David
    Liu, Yifeng
    Lucero, Melanie
    Meier, Genevieve
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
    Nobuharu Tamaki
    Toshifumi Tada
    Masayuki Kurosaki
    Yutaka Yasui
    Hironori Ochi
    Toshie Mashiba
    Azusa Sakamoto
    Hiroyuki Marusawa
    Ryoichi Narita
    Yasushi Uchida
    Takehiro Akahane
    Masahiko Kondo
    Nami Mori
    Shintaro Takaki
    Keiji Tsuji
    Haruhiko Kobashi
    Atsunori Kusakabe
    Koichiro Furuta
    Hirotaka Arai
    Michiko Nonogi
    Chikara Ogawa
    Takashi Sato
    Takashi Tamada
    Shinichiro Nakamura
    Chitomi Hasebe
    Kaoru Tsuchiya
    Namiki Izumi
    Investigational New Drugs, 2022, 40 : 1290 - 1297
  • [23] Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2022, 11 (05) : 399 - 406
  • [24] Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
    Wang, K.
    Sun, H.
    Bai, X.
    Huang, Z-Y.
    Song, T.
    Chen, M.
    Kuang, M.
    Xiang, B.
    Zeng, Y.
    Liu, L-X.
    Li, D.
    Chen, Y.
    Cai, J.
    Xing, B.
    Peng, T.
    Zhang, X.
    Zhu, X.
    Zhou, J.
    Fan, J.
    Shen, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S1541 - S1541
  • [25] Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response
    Kuzuya, Teiji
    Kawabe, Naoto
    Muto, Hisanori
    Tachi, Yoshihiko
    Ukai, Takeshi
    Wada, Yuryo
    Komura, Gakushi
    Nakano, Takuji
    Tanaka, Hiroyuki
    Nakaoka, Kazunori
    Ohno, Eizaburo
    Funasaka, Kohei
    Nagasaka, Mitsuo
    Miyahara, Ryoji
    Hirooka, Yoshiki
    CURRENT ONCOLOGY, 2024, 31 (10) : 6218 - 6231
  • [26] Impact of renal function on the prognosis of patients receiving Atezolizumab/Bevacizumab combination therapy and Lenvatinib monotherapy for unresectable hepatocellular carcinoma
    Takada, Hitomi
    Yamashita, Koji
    Osawa, Leona
    Komiyama, Yasuyuki
    Nakakuki, Natsuko
    Muraoka, Masaru
    Suzuki, Yuichiro
    Sato, Mitsuaki
    Takano, Shinichi
    Fukasawa, Mitsuharu
    Yamaguchi, Tatsuya
    Maekawa, Shinya
    Takahashi, Kazuya
    Uchimura, Kohei
    Enomoto, Nobuyuki
    ONCOLOGY, 2023, 101 (10) : 609 - 623
  • [27] Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery
    Zeng, Zhen-Xin
    Wu, Jia-Yi
    Wu, Jun-Yi
    Zhang, Zhi-Bo
    Wang, Kai
    Zhuang, Shao-Wu
    Li, Bin
    Zhou, Jian-Yin
    Lin, Zhong-Tai
    Li, Shu-Qun
    Li, Yi-Nan
    Fu, Yang-Kai
    Yan, Mao-Lin
    LIVER CANCER, 2024, 13 (05) : 498 - 508
  • [28] Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Kosaka, Hisashi
    Naganuma, Atsushi
    Koizumi, Yohei
    Nakamura, Shinichiro
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    CANCER MEDICINE, 2023, 12 (07): : 7772 - 7783
  • [29] EARLY TUMOR RESPONSE AND SAFETY OF ATEZOLIZUMAB PLUS BEVACIZUMAB FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA IN REAL WORLD PRACTICE
    Ando, Yuwa
    Kawaoka, Tomokazu
    Amioka, Kei
    Uchikawa, Shinsuke
    Kodama, Kenichiro
    Fujino, Hatsue
    Nakahara, Takashi
    Ono, Atsushi
    Murakami, Eisuke
    Yamauchi, Masami
    Imamura, Michio
    Aikata, Hiroshi
    HEPATOLOGY, 2021, 74 : 636A - 637A
  • [30] Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma
    Toshida, Katsuya
    Itoh, Shinji
    Yoshiya, Shohei
    Nagao, Yoshihiro
    Tomino, Takahiro
    Izumi, Takuma
    Iseda, Norifumi
    Toshima, Takeo
    Ninomiya, Mizuki
    Yoshizumi, Tomoharu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (03) : 576 - 586
12345